Sanofi is facing competition in it big-selling long acting insulin Lantus in Europe, after the Commission approved a biosimilar rival developed by Eli Lilly and Boehringer Ingelheim.
Sanofi is facing competition for its big-selling long-acting insulin Lantus in Europe, after the Commission approved a biosimilar rival developed by Eli Lilly and Boehringer Ingelheim.